Geisinger Clinic   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Pennsylvania NJ United States (1985)

Organization Overview

First Clinical Trial
1985
NCT00000492
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Autism & Developmental Medicine Institute Geisinger Health System | C. Liam Dwyer | Daniel Horwitz | Geisinger Clinic | Gerard Cush | John B Bulger, DO | Mark Seeley | Sean Devitt

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Pain (Phase 4)

Cardiovascular Diseases (Phase 3)

Cluster Headache (Phase 1)

Coronary Disease (Phase 3)

Death, Sudden (Phase 3)

Death, Sudden, Cardiac (Phase 3)

Diabetes Mellitus, Type 2 (Phase 4)

Femoral Fractures (Phase 4)

Fractures, Bone (Phase 4)

Fragile X Syndrome (Phase 2)

Glioblastoma (Phase 2)

Headache (Phase 1)

Head and Neck Neoplasms (Phase 2)

Heart Diseases (Phase 3)

Myocardial Infarction (Phase 3)

Myocardial Ischemia (Phase 3)

Radius Fractures (Phase 4)

Surgical Wound Infection (Phase 4)

Syndrome (Phase 2)

Vasospasm, Intracranial (Phase 4)

Ventricular Fibrillation (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 21
  • # of Trial APIs: 28